IBDEI0GB ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7062,1,4,0)
 ;;=4^I25.119
 ;;^UTILITY(U,$J,358.3,7062,2)
 ;;=^5007111
 ;;^UTILITY(U,$J,358.3,7063,0)
 ;;=I50.32^^58^461^2
 ;;^UTILITY(U,$J,358.3,7063,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7063,1,3,0)
 ;;=3^Chronic Diastolic Congestive Heart Failure
 ;;^UTILITY(U,$J,358.3,7063,1,4,0)
 ;;=4^I50.32
 ;;^UTILITY(U,$J,358.3,7063,2)
 ;;=^5007245
 ;;^UTILITY(U,$J,358.3,7064,0)
 ;;=E08.43^^58^462^8
 ;;^UTILITY(U,$J,358.3,7064,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7064,1,3,0)
 ;;=3^DM d/t Underlying Condition w/ Diabetic Auto Neuropathy
 ;;^UTILITY(U,$J,358.3,7064,1,4,0)
 ;;=4^E08.43
 ;;^UTILITY(U,$J,358.3,7064,2)
 ;;=^5002525
 ;;^UTILITY(U,$J,358.3,7065,0)
 ;;=E11.21^^58^462^2
 ;;^UTILITY(U,$J,358.3,7065,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7065,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,7065,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,7065,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,7066,0)
 ;;=E11.40^^58^462^3
 ;;^UTILITY(U,$J,358.3,7066,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7066,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Neuropathy
 ;;^UTILITY(U,$J,358.3,7066,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,7066,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,7067,0)
 ;;=E11.65^^58^462^4
 ;;^UTILITY(U,$J,358.3,7067,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7067,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,7067,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,7067,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,7068,0)
 ;;=E11.8^^58^462^1
 ;;^UTILITY(U,$J,358.3,7068,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7068,1,3,0)
 ;;=3^DM Type 2 w/ Complications
 ;;^UTILITY(U,$J,358.3,7068,1,4,0)
 ;;=4^E11.8
 ;;^UTILITY(U,$J,358.3,7068,2)
 ;;=^5002665
 ;;^UTILITY(U,$J,358.3,7069,0)
 ;;=E11.9^^58^462^7
 ;;^UTILITY(U,$J,358.3,7069,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7069,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,7069,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,7069,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,7070,0)
 ;;=E13.40^^58^462^10
 ;;^UTILITY(U,$J,358.3,7070,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7070,1,3,0)
 ;;=3^DM w/ Diabetic Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,7070,1,4,0)
 ;;=4^E13.40
 ;;^UTILITY(U,$J,358.3,7070,2)
 ;;=^5002684
 ;;^UTILITY(U,$J,358.3,7071,0)
 ;;=E13.43^^58^462^9
 ;;^UTILITY(U,$J,358.3,7071,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7071,1,3,0)
 ;;=3^DM w/ Diabetic Auto Neuropathy
 ;;^UTILITY(U,$J,358.3,7071,1,4,0)
 ;;=4^E13.43
 ;;^UTILITY(U,$J,358.3,7071,2)
 ;;=^5002687
 ;;^UTILITY(U,$J,358.3,7072,0)
 ;;=E11.10^^58^462^6
 ;;^UTILITY(U,$J,358.3,7072,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7072,1,3,0)
 ;;=3^DM Type 2 w/ Ketoacidosis w/o Coma
 ;;^UTILITY(U,$J,358.3,7072,1,4,0)
 ;;=4^E11.10
 ;;^UTILITY(U,$J,358.3,7072,2)
 ;;=^5151300
 ;;^UTILITY(U,$J,358.3,7073,0)
 ;;=E11.11^^58^462^5
 ;;^UTILITY(U,$J,358.3,7073,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7073,1,3,0)
 ;;=3^DM Type 2 w/ Ketoacidosis w/ Coma
 ;;^UTILITY(U,$J,358.3,7073,1,4,0)
 ;;=4^E11.11
 ;;^UTILITY(U,$J,358.3,7073,2)
 ;;=^5151301
 ;;^UTILITY(U,$J,358.3,7074,0)
 ;;=E06.3^^58^463^1
 ;;^UTILITY(U,$J,358.3,7074,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7074,1,3,0)
 ;;=3^Autoimmune Thyroiditis
 ;;^UTILITY(U,$J,358.3,7074,1,4,0)
 ;;=4^E06.3
 ;;^UTILITY(U,$J,358.3,7074,2)
 ;;=^5002495
 ;;^UTILITY(U,$J,358.3,7075,0)
 ;;=E26.09^^58^463^5
